NCT00295477View on ClinicalTrials.gov

Evaluate the Tolerability and Therapeutic Effects of Repeated Doses of Autologous T Cells With VRX496 in HIV

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

April 30, 2010

Study Completion Date

December 31, 2013

Conditions
HIV
Interventions
GENETIC

VRX496

In Step 1 of the protocol, each subject will receive up to 2 cycles of VRX496. Each treatment cycle consists of 3 infusions of VRX496.

Trial Locations (1)

19104

University of Pennsylania, Philadelphia

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

University of Pennsylvania

OTHER

NCT00295477 - Evaluate the Tolerability and Therapeutic Effects of Repeated Doses of Autologous T Cells With VRX496 in HIV | Biotech Hunter | Biotech Hunter